Publication Type : Conference Proceedings
Publisher : Journal of Clinical Oncology
Source : India. In ASCO 2021. 10.1200/JCO.2021.39.15_suppl.e15517
Url : https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.e15517
Campus : Kochi
School : School of Medicine
Year : 2021
Abstract : Background: DPYD deficiency is present in 3-5% of patients. The risk of treatment-related death in DPYD mutation carriers who receive fluoropyrimidine chemotherapy has been estimated at 3-10%. There is growing data in support of widespread screening for DPYD deficiency prior to fluoropyrimidine chemotherapy. The purpose of our study was to identify the prevalence of DPYD deficiency among patients receiving 5-fluorouracil (5FU) or capecitabine based combination chemotherapy, and to analyse the toxicity profile among the DPYD deficient group.
Cite this Research Publication : Pavithran K, Ariyannur P, Jayamohanan H, Philip A, Jose WM, Soman S. Dihydropyrimidine dehydrogenase deficiency in patients treated with 5FU or capecitabine based regimens: A single center experience from South India. In ASCO 2021. 10.1200/JCO.2021.39.15_suppl.e15517